The ATAD3A Knockout LoVo Polyclonal Cells offer a CRISPR/Cas9-edited polyclonal knockout cell population for studying ATAD3A loss-of-function in the LoVo colorectal adenocarcinoma line. This heterogeneous pool arises from bulk gene disruption without clonal selection, enabling assessment of ATAD3A??s overall functions while preserving population diversity. As a research tool, it supports investigations into mitochondrial biology, apoptosis regulation, and oncogenic signaling in a clinically relevant colorectal cancer background.
LoVo cells, derived from a lymph node metastasis in a 56-year-old male, serve as a well-characterized model for metastatic colorectal cancer. Their epithelial origin and invasive properties make them ideal for studying cancer progression, metastasis, and drug resistance. Introducing ATAD3A knockout into this genetic context allows direct probing of gene function in a setting that recapitulates advanced disease.
ATAD3A is a mitochondrial inner membrane AAA-ATPase that governs mitochondrial dynamics, cholesterol transport, and mtDNA maintenance. Regulated by STAT3, MYC, and Wnt/???catenin, it interacts with DRP1 to promote fission and with HSP60, SAM50 for proteostasis. Downstream, ATAD3A upregulates BCL2, downregulates BAX/BAK, and modulates TFAM and mtSSB, thereby enhancing cell survival via mTOR and STAT3 pathways. This knockout model disrupts these interactions, implicating mitochondrial dysfunction and apoptosis sensitization.
In LoVo cells, ATAD3A knockout provides a platform to dissect mitochondrial contributions to metastatic behavior. As ATAD3A sustains mitochondrial fission and anti-apoptotic tone, its loss may reveal dependencies in migration and survival under stress. This model facilitates examination of cholesterol trafficking and mitochondrial quality control in the context of colorectal cancer metastasis.
Researchers employ this model in western blotting, RT?qPCR, and immunofluorescence for expression analysis; flow cytometry and MTT assays for viability and apoptosis; Transwell migration for invasion; drug sensitivity tests; and MitoTracker staining for mitochondrial morphology. These applications advance understanding of ATAD3A in colorectal cancer, drug resistance, and mitochondrial pathobiology. For further information, please contact Ascent Research.
